摘要
目的:观察自拟理肠汤治疗脾虚湿困型溃疡性结肠炎(Ulcerative Colitis,UC)的临床疗效及安全性。方法:选取2017年2月-2019年2月我院收治的60例脾虚湿困型溃疡性结肠炎患者作为研究对象,根据随机数字表将患者分为对照组和观察组,每组各30例。对照组口服美沙拉秦缓释颗粒进行治疗,观察组在此基础上应用自拟理肠汤进行治疗。对比两组患者治疗8周后的综合疗效、中医症状量化评分、改进Baron评分以及治疗期间的不良反应。结果:治疗结束后,观察组治疗总有效率高于对照组,差异具有统计学意义(P<0.05)。经过治疗后,两组患者中医症状量化总分、腹泻次数评分、腹痛及频率评分、腹胀程度及频率评分、大便黏液评分、里急后重感评分及改进Baron评分均低于治疗前,差异具有统计学意义(P<0.05),且观察组患者中医症状量化总分、腹泻次数评分、腹痛及频率评分、腹胀程度及频率评分、大便黏液评分、里急后重感评分及改进Baron评分低于对照组,差异均具有统计学意义(P<0.05)。两组患者治疗期间均未发生药物不良反应。结论:自拟理肠汤治疗脾虚湿困型溃疡性结肠炎效果确切,可明显减轻患者中医症状,改善患者肠镜下肠黏膜变化,且无明显不良反应,具有较好的临床应用价值。
Objective:To observe the clinical efficacy and safety of the Lichang decoction(理肠汤)on ulcerative colitis of the Pixu Shikun type(脾虚湿困型).Methods:From February 2017 to February 2019,60 cases were divided into the control group and the observation group,30 cases in each group.The control group was treated with mesalazine orally.The observation group was treated with the Lichang decoction.Results:After treatment,the total efficiency in the observation group was higher than that in the control group(P<0.05).After treatment,the TCM total scores,diarrhea scores,abdominal pain and frequency scores,abdominal distension and frequency scores,fecal mucus scores,post-emergency resilience scores and Baron scores were lower than before treatment(P<0.05),and those were lower in the observation group than the control group(P<0.05).No adverse drug reactions occurred during the treatment period in both groups.Conclusion:The Lichang decoction is effective on ulcerative colitis of the Pixu Shikun type.It can significantly alleviate the symptoms and improve the intestinal mucosal changes,without adverse reactions.It has good clinical application value.
出处
《中医临床研究》
2020年第10期119-122,共4页
Clinical Journal Of Chinese Medicine
关键词
理肠汤
溃疡性结肠炎
肠黏膜
脾虚湿困
The Lichang decoction
Ulcerative colitis
Intestinal mucosa
Pixu Shikun
